Medindia

X

Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference

Thursday, May 15, 2008 General News J E 4
Advertisement
WESTFORD, Mass., May 15 Cynosure, Inc.(Nasdaq: CYNO), a leading developer and manufacturer of a broad array oflight-based aesthetic treatment systems, today announced that its seniormanagement will present at the 2008 Citi Investment Research Global HealthCare Conference, taking place at the Hilton New York.

Cynosure's presentation will be webcast live over the Internet beginningat 2:00 p.m. (ET) Thursday, May 22, 2008. President and Chief ExecutiveOfficer Michael Davin and Chief Financial Officer Timothy Baker plan todiscuss Cynosure's business outlook, growth strategy and recent financialresults. To access the live or archived webcast, visit the "InvestorRelations" portion of Cynosure's website at www.cynosure.com.

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that areused by physicians and other practitioners to perform non-invasive andminimally invasive procedures to remove hair, treat vascular lesions,rejuvenate skin through the treatment of shallow vascular and pigmentedlesions, laser lipolysis and temporarily reduce the appearance of cellulite.Cynosure's products include a broad range of laser and other light-basedenergy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, aswell as intense pulsed light. Cynosure was founded in 1991. For corporate orproduct information, contact Cynosure at 800-886-2966, or visithttp://www.cynosure.com.Contact: Scott Solomon Vice President Sharon Merrill Associates, Inc. 617.542.5300 cyno@investorrelations.com

SOURCE Cynosure, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
OmniGuide(R) Secures $25 Million in Funding to Sup...
S
Huifeng Bio-Pharmaceutical (HFGB) Announces No Ear...